Study on monomer functional suitability toward sofosbuvir in molecularly imprinted polymer: In silico and experimental study

Study on monomer functional suitability toward sofosbuvir in molecularly imprinted polymer: In silico and experimental study

Sofosbuvir (SOF) is an anti-HCV (Hepatitis C Virus) used as an off-label drug in treating COVID-19 and the usage requires good therapeutic drug monitoring, with analytical and suitable sample preparation methods. Therefore, this research aimed to apply in silico and laboratory testing in preparing S...

Full description

Bibliographic Details
Main Authors:	Hilda Aprilia Wisnuwardhani, Slamet Ibrahim, Rino Rakhmata Mukti, Sophi Damayanti
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Composites Part C: Open Access
Subjects:	Sofosbuvir Imprinted polymer In silico study
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666682023000610

Similar Items

Molecularly-Imprinted SERS: A Potential Method for Bioanalysis
by: Hilda Aprilia Wisnuwardhani, et al.
Published: (2022-09-01)

Purification of Andrographolide Methanolic Extract Using Molecularly Imprinted Polymer Prepared by Precipitation Polymerization
by: Wiwin Winingsih, et al.
Published: (2022-04-01)

Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
by: Eman G. Behiry, et al.
Published: (2018-11-01)

Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19?
by: Shahnaz Sali, et al.
Published: (2020-12-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
by: Aqsa Naseer
Published: (2017-12-01)

EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN HEMODIALYSIS PATIENTS SUFFERING WITH HEPATITIS C INFECTION
by: Yasir Mehmood, et al.
Published: (2021-02-01)

Site-specific post-imprinting modification of molecularly imprinted polymer nanocavities with a modifiable functional monomer for prostate cancer biomarker recognition
by: Hiroki Matsumoto, et al.
Published: (2019-12-01)

Respiratory adverse effects of Sofosbuvir-based regimens for treatment of chronic hepatitis C virus
by: Dina Abouelkheir Abdalla, et al.
Published: (2017-04-01)

Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report
by: Alireza Heidari Bakavoli, et al.
Published: (2020-09-01)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018-09-01)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018-09-01)

Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience
by: Bandar Al-Judaibi, et al.
Published: (2018-05-01)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
by: Eiichi Ogawa, et al.
Published: (2020-09-01)

Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen
by: Amr Alnoby*, et al.
Published: (2021-08-01)

Effectiveness of Sofosbuvir regime in Hepatitis C virus infection in hemodialysis Pakistani patients: Single Centre Study
by: Rahmat Ali Khan, et al.
Published: (2017-12-01)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
by: Hee Yeon Seo, et al.
Published: (2020-05-01)

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
by: Seong Hee Kang, et al.
Published: (2021-01-01)

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Study of the Preparation and Properties of Chrysin Binary Functional Monomer Molecularly Imprinted Polymers
by: Long Li, et al.
Published: (2022-07-01)

The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV
by: Mohamed AbdElrahman, et al.
Published: (2023-01-01)

Use of sofosbuvir in chronic kidney disease: Is it necessary?
by: Tae Seop Lim, et al.
Published: (2017-12-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study
by: Mekky MA, et al.
Published: (2019-01-01)

Sofosbuvir: A Potential Treatment for Ebola
by: Sandra E. Reznik, et al.
Published: (2018-10-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Synthesis and characterization of a molecularly imprinted polymer for Pb2+ uptake using 2-vinylpyridine as the complexing monomer
by: Yusof, Nor Azah, et al.
Published: (2010)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD
by: Daniela Gabbia, et al.
Published: (2022-04-01)

Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir
by: Andreas Jonathan, et al.
Published: (2020-07-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment
by: Sherif Gamal, et al.
Published: (2023-08-01)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
by: Elshahat Ibrahem Ismail, et al.
Published: (2018-03-01)

Effectiveness of Combination Therapy of Sofosbuvir and Daclatasvir in Hepatitis C Positive Hemodialysis Patients Presenting to a Tertiary Care Hospital
by: Qurat Ul Ain, et al.
Published: (2023-10-01)

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
by: Wafaa M. Ezzat, et al.
Published: (2024-01-01)